Oxford Biomedica PLC Board Change (2613D)
25 June 2019 - 4:01PM
UK Regulatory
TIDMOXB
RNS Number : 2613D
Oxford Biomedica PLC
25 June 2019
Board Change: Oxford Biomedica Appoints Robert Ghenchev as
Non-Executive Director
London, UK - 25 June 2019: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, today announces the appointment of Robert Ghenchev
to the Group's Board as a Non-Executive Director as of 24 June
2019.
Mr Ghenchev is currently a Director in the Principal Investments
team of Novo Holdings with responsibility over Growth Equity
investments. Prior to joining Novo Holdings, Robert was Senior Vice
President at Moelis & Company in London where he was focused on
mergers and acquisitions within the Healthcare Industry. Prior to
Moelis, Robert was part of the UK Mergers & Acquisitions team
at Deutsche Bank in London.
Mr Ghenchev holds a J.Hons. B.A. degree in Finance and Economics
from McGill University and a M.Sc. degree in Financial Economics
from the University of Oxford.
There are no disclosures required to be made in accordance with
LR 9.6.13R.
Commenting on the announcement, Lorenzo Tallarigo, Chairman of
Oxford Biomedica, said: "I am delighted to welcome Robert to the
Board of Oxford Biomedica. Robert has a proven track record of
helping to grow life sciences companies in the US and Europe as an
advisor and an investor. His industry knowledge is directly aligned
with Oxford Biomedica's strategy to take advantage of our leading
position with lentiviral vectors, both with our partners and
through our own in-house expertise."
Commenting on his appointment, Robert Ghenchev, said: "Novo
Holdings is committed to supporting companies developing
cutting-edge science that makes a real difference to patients and
society. Oxford Biomedica is a global scientific and manufacturing
leader in lentiviral vectors and I am excited by the prospects for
the Group which is at the forefront of what is a gene and cell
therapy revolution. I am looking forward to working with Oxford
Biomedica and supporting the Group going forward."
From 24 June 2019, the composition of the Board of Oxford
Biomedica is as follows:
-- Dr. Lorenzo Tallarigo, Non-Executive Chairman
-- John Dawson, Chief Executive Officer
-- Stuart Paynter, Chief Financial Officer
-- Dr. Andrew Heath, Independent Non-Executive Director
-- Stuart Henderson, Independent Non-Executive Director
-- Martin Diggle, Non-Executive Director
-- Dr. Heather Preston, Independent Non-Executive Director
-- Robert Ghenchev; Non-Executive Director
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Stuart Paynter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK
Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations,
through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than
430 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOACKQDKCBKDDAB
(END) Dow Jones Newswires
June 25, 2019 02:01 ET (06:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024